| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3602 | 2014 |
| Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... European urology 71 (2), 151-154, 2017 | 484 | 2017 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 465 | 2020 |
| Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised … M Smith, C Parker, F Saad, K Miller, B Tombal, QS Ng, M Boegemann, ... The Lancet Oncology 20 (3), 408-419, 2019 | 416 | 2019 |
| The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage Y Fukuda, M Ishizaki, Y Masuda, G Kimura, O Kawanami, Y Masugi The American journal of pathology 126 (1), 171, 1987 | 403 | 1987 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 236 | 2022 |
| Automated acquisition of explainable knowledge from unannotated histopathology images Y Yamamoto, T Tsuzuki, J Akatsuka, M Ueki, H Morikawa, Y Numata, ... Nature communications 10 (1), 5642, 2019 | 149 | 2019 |
| PREVAIL Investigators: Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... N Engl J Med 371 (5), 424-433, 2014 | 147 | 2014 |
| Insulin‐like growth factor (IGF) system components in human prostatic cancer cell‐lines: LNCaP, DU145, and PC‐3 cells G Kimura, J Kasuya, S Giannini, Y Honda, S Mohan, MH Kawachi, ... International journal of urology 3 (1), 39-46, 1996 | 147 | 1996 |
| Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. TM Beer, AJ Armstrong, CN Sternberg, CS Higano, P Iversen, Y Loriot, ... Journal of Clinical Oncology 32 (4_suppl), LBA1-LBA1, 2014 | 115 | 2014 |
| The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naive metastatic castration-resistant prostate cancer CP Evans, CS Higano, T Keane, G Andriole, F Saad, P Iversen, K Miller, ... European urology 70 (4), 675-683, 2016 | 109 | 2016 |
| Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors SL Li, H Goko, ZD Xu, G Kimura, Y Sun, MH Kawachi, TG Wilson, ... Cell and tissue research 291, 469-479, 1998 | 84 | 1998 |
| Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT M Shiiba, K Ishihara, G Kimura, T Kuwako, N Yoshihara, H Sato, Y Kondo, ... Annals of nuclear medicine 26, 138-145, 2012 | 80 | 2012 |
| Cyclooxygenase‐2 expression and relationship to tumour progression in human renal cell carcinoma Y Hashimoto, Y Kondo, G Kimura, I Matsuzawa, S Sato, M Ishizaki, ... Histopathology 44 (4), 353-359, 2004 | 76 | 2004 |
| Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study Y Tomita, S Fukasawa, N Shinohara, H Kitamura, M Oya, M Eto, K Tanabe, ... Japanese journal of clinical oncology 47 (7), 639-646, 2017 | 65 | 2017 |
| Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer Y Senga, G Kimura, T Hattori, K Yoshida Urology 48 (5), 703-710, 1996 | 63 | 1996 |
| Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study RJ Motzer, C Porta, M Eto, T Powles, V Grünwald, TE Hutson, B Alekseev, ... Journal of clinical oncology 42 (11), 1222-1228, 2024 | 62 | 2024 |
| High-frequency endoluminal ultrasonography for staging transitional cell carcinoma of the bladder K Horiuchi, N Tsuboi, H Shimizu, I Matsuzawa, G Kimura, K Yoshida, ... Urology 56 (3), 404-407, 2000 | 53 | 2000 |
| Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy Y Yamamoto, CP Offord, G Kimura, S Kuribayashi, H Takeda, S Tsuchiya, ... British journal of cancer 115 (2), 195-202, 2016 | 51 | 2016 |
| Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study Y Tomita, S Fukasawa, N Shinohara, H Kitamura, M Oya, M Eto, K Tanabe, ... Japanese journal of clinical oncology 49 (6), 506-514, 2019 | 50 | 2019 |